The presence of SMI is decisive for the endoscopic technique used by the specialist to treat polyps and determines whether additional systemic therapy should be initiated. The detection of SMI in LNPCPs is currently poor [1]. Therefore, the current study aimed to develop an evidence-based, easy-to-use, clinical decision support tool for endoscopists to detect SMI in colorectal polyps [2].
Dr Lynn Debels (University Hospital Ghent, Belgium) and colleagues created an algorithm which used the blink impression of the endoscopist, scanning for an overt demarcated irregular area, and scoring several parameters (size, location, morphology, Paris classification of early cancer) if no overt demarcated area was present to estimate the risk of SMI. The authors prospectively selected 20 LNPCPs with help from experts. Endoscopy videos were standardised, and a 10-minute educational video was developed to explain the use of the clinical decision tool. In total, 37 endoscopists with a broad range of experience estimated the risk of SMI in all 20 selected LNPCPs, following the algorithm. Participant observations were compared with expert opinions and histopathology.
Overall, the participating endoscopists could estimate the presence of SMI with an accuracy of 75.0%, with a negative predictive value (NPV) of 93.2% and a positive predictive value (PPV) of 70.4%. The blink impression of the participants could predict SMI with an accuracy of 72.3%. The NPV of their blink impression was 97.5%, whereas the PPV was 41.8%. The presence of an overt demarcated area was detected with an accuracy of 78.6%. Again, the NPV was higher than the PPV (97.6% and 48.2%, respectively). Expert and participant observations of covert SMI parameters showed an overlap ranging between 61.8% (morphology) and 94.8% (location). In this study, 71.3% of the cases would receive the correct treatment, whereas 13.1% would receive undertreatment (mostly high-risk patients), and 15.6% would be subjected to overtreatment.
- Tate DJ, et al. Endosc Int Open 2020; 8(3):E445-E455
- Debels L, et al. The accuracy of human detection of submucosal invasive cancer in large non-pedunculated colorectal polyps: analysis of 739 individual assessments of large non-pedunculated colorectal polyps using a novel clinical decision support tool. LB01, UEG Week 2021 Virtual Congress, 03–05 October.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Diagnoses of wild-type transthyretin amyloid cardiomyopathy rising, but often late Next Article
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy »
« Diagnoses of wild-type transthyretin amyloid cardiomyopathy rising, but often late Next Article
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy »
Table of Contents: UEGW 2021
Featured articles
Updates in Biologics
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Long-term efficacy data of dupilumab for eosinophilic oesophagitis
Updates in Small Molecules
Upadacitinib efficacious and safe as maintenance therapy for UC
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics
Rapid symptom control for UC patients on upadacitinib
Filgotinib demonstrates promising results for various lines of therapy in UC
Filgotinib demonstrates long-term corticosteroid-sparing effects in UC
Long-term benefits of tofacitinib for substantial proportion of UC patients
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
First pharmacological therapy with clear efficacy in coeliac disease patients
Endoscopy
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy
Novel tool can reliably exclude submucosal invasion in colorectal polyps
Other Updates
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Related Articles
May 28, 2018
Genetic predisposition for gut barrier dysfunction
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com